Thrombogenicity and Early Vascular Healing Response in Metallic Biodegradable Polymer-Based and Fully Bioabsorbable Drug-Eluting Stents

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Circulation. Cardiovascular Interventions

• Publication date

  2015-06-01

• Fields of study

  Medicine, Engineering

• Identifiers
  DOI 10.1161/CIRCINTERVENTIONS.115.002427PMID 26022535
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial.

  2016cited by this paper
• Immediate and midterm outcomes following primary PCI with bioresorbable vascular scaffold implantation in patients with ST-segment myocardial infarction: insights from the multicentre "Registro ABSORB Italiano" (RAI registry).

  2015cited by this paper
• A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.

  2015cited by this paper
• Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry.

  2015cited by this paper
• New stent surface materials: the impact of polymer-dependent interactions of human endothelial cells, smooth muscle cells, and platelets.

  2014cited by this paper
• Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes.

  2014cited by this paper
• Causes of early stent thrombosis in patients presenting with acute coronary syndrome: an ex vivo human autopsy study.

  2014cited by this paper
• Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent

  2013cited by this paper
• Detection of Tissue Factor Antigen and Coagulation Activity in Coronary Artery Thrombi Isolated from Patients with ST-Segment Elevation Acute Myocardial Infarction

  2013cited by this paper
• Everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with ST-segment elevation myocardial infarction (STEMI).

  2013cited by this paper
• Preclinical evaluation of second-generation everolimus- and zotarolimus-eluting coronary stents.

  2013cited by this paper
• Impact of Stent Surface on Thrombogenicity and Vascular Healing: A Comparative Analysis of Metallic and Polymeric Surfaces

  2013influential reference
• Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial.

  2012cited by this paper
• Restenosis in bare metal and drug-eluting stents: distinct mechanistic insights from histopathology and optical intravascular imaging.

  2012cited by this paper
• Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis

  2012cited by this paper
• Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials.

  2012cited by this paper
• Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.

  2012cited by this paper
• S6K1 and mTOR regulate Rac1-driven platelet activation and aggregation.

  2011cited by this paper
• Stent Thrombogenicity Early in High-Risk Interventional Settings Is Driven by Stent Design and Deployment and Protected by Polymer-Drug Coatings

  2011cited by this paper
• Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial.

  2011cited by this paper
• A method to develop mock arteries suitable for cell seeding and in-vitro cell culture experiments.

  2010cited by this paper
• Endothelial cell recovery, acute thrombogenicity, and monocyte adhesion and activation on fluorinated copolymer and phosphorylcholine polymer stent coatings.

  2010cited by this paper
• Endothelial cell recovery between comparator polymer-based drug-eluting stents.

  2008cited by this paper
• Pathological Correlates of Late Drug-Eluting Stent Thrombosis: Strut Coverage as a Marker of Endothelialization

  2007cited by this paper
• mTOR-dependent synthesis of Bcl-3 controls the retraction of fibrin clots by activated human platelets.

  2007cited by this paper
• Stent thrombosis in randomized clinical trials of drug-eluting stents.

  2007influential reference
• Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk.

  2006cited by this paper
• Alterations in regional vascular geometry produced by theoretical stent implantation influence distributions of wall shear stress: analysis of a curved coronary artery using 3D computational fluid dynamics modeling

  2006cited by this paper
• Cardiology is flow.

  2006cited by this paper
• Influence of topography on endothelialization of stents: clues for new designs.

  2000cited by this paper
• Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor.

  2000cited by this paper
• Blood-borne tissue factor: another view of thrombosis.

  1999cited by this paper
• Coronary thrombosis.

  1996cited by this paper
• Guide for the Care and Use of Laboratory Animals

  1996cited by this paper
• Endovascular stent design dictates experimental restenosis and thrombosis.

  1995cited by this paper
• Coronary Thrombosis

  1957cited by this paper
• Improved Safety and Reduction in Stent Thrombosis Associated With Biodegradable Polymer-Based Biolimus-Eluting Stents Versus Durable Polymer-Based Sirolimus-Eluting Stents in Patients With Coronary Artery Disease Final 5-Year Report (Limus Eluted From A Durable Versus ERodable Stent Coating) Randomi

  year unknowncited by this paper

• A minimally invasive animal model of atherosclerosis and neointimal hyperplasia for translational research

  2025cites this paper
• Polymers for Biomedical Applications: the Quest for Treating Cardiovascular Diseases

  2025cites this paper
• Dual-targeted molecular MRI nanoprobe for precision cardiovascular imaging

  2025cites this paper
• The efficacy of biodegradable polymer everolimus-eluting stents in patients with cardiac allograft vasculopathy

  2025cites this paper
• Early Oral Anticoagulation Monotherapy After PCI: Insights from the POEM Trial.

  2025cites this paper
• Vascular Restoration With Bioresorbable Scaffolds: Epic Revolution or Pyrrhic Victory?

  2025cites this paper
• Early “Scars” and Long-Term Promise of Bioresorbable Scaffolds: A Decade of Evidence From SCAAR

  2025cites this paper
• Research Progress of Metal Degradable Cardiovascular Stent

  2025cites this paper
• The preclinical study of biocompatibility of tyrosine polycarbonate bioresorbable scaffold in small caliber porcine peripheral arteries

  2025cites this paper
• Innovations in Vascular Repair from Mechanical Intervention to Regenerative Therapies

  2025cites this paper
• One-month DAPT after biodegradable-polymer everolimus-eluting stent implantation in patients at high-bleeding risk: an individual patient data pooled analysis of the SENIOR and POEM trials

  2024cites this paper
• Current situation and overview of resorbable magnesium scaffolds: a perspective for overcoming the remaining issues of polymeric bioresorbable scaffold

  2024cites this paper
• One- Versus Three-Month Dual Antiplatelet Therapy in High Bleeding Risk Patients With Chronic Kidney Disease.

  2024cites this paper
• Stent Thrombosis and Restenosis with Contemporary Drug-Eluting Stents: Predictors and Current Evidence

  2023cites this paper
• Genetic Backgrounds Associated With Stent Thrombosis

  2023cites this paper
• Changes of plasma Rap1A levels in patients with in-stent restenosis after percutaneous coronary intervention and the underlying mechanisms.

  2023cites this paper
• 3D-printed, citrate-based bioresorbable vascular scaffolds for coronary artery angioplasty

  2023cites this paper
• One-Month Dual Antiplatelet Therapy in Patients With Chronic and Acute Coronary Syndromes Treated With Bioresorbable Polymer Everolimus-Eluting Stents.

  2023cites this paper
• Short Versus Long-Term Dual Antiplatelet Therapy in Patients at High Bleeding Risk Undergoing PCI in Contemporary Practice: A Systemic Review and Meta-analysis

  2023cites this paper
• Novel bioresorbable scaffolds and lessons from recent history.

  2023cites this paper
• Biodegradable polymer everolimus-eluting stents versus contemporary drug-eluting stents: a systematic review and meta‑analysis

  2023cites this paper
• Sirolimus-eluting stents with ultrathin struts versus everolimus-eluting stents for patients undergoing percutaneous coronary intervention: final three-year results of the TALENT trial.

  2022cites this paper
• Short dual antiplatelet therapy in patients with high bleeding risk undergoing percutaneous coronary intervention: a systematic review and meta-analysis

  2022cites this paper
• Challenges of the newer generation of Resorbable magnesium scaffolds: Lessons from failure mechanisms of the past generation.

  2022cites this paper
• Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events?

  2022cites this paper
• Optical Coherence Tomography: An Eye Into the Coronary Artery

  2022cites this paper
• Long-Term Outcomes After Implantation of Magnesium-Based Bioresorbable Scaffolds—Insights From an All-Comer Registry

  2022cites this paper
• Dual surface modification of poly(L-lactide) scaffold achieved by thermal incorporation of aligned nanofiber and click immobilization of VEGF to enhance endothelialization and blood compatibility

  2022cites this paper
• One‐Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus‐Eluting Stents in High Bleeding Risk Patients

  2022cites this paper
• Pathological assessment of very late bare metal stent thrombosis in the left main coronary artery: a case report

  2021cites this paper
• Long-term outcomes after treatment of in-stent restenosis using the Absorb everolimus-eluting bioresorbable scaffold

  2021cites this paper
• Inflammation as a determinant of healing response after coronary stent implantation

  2021influential citation
• Optimized bioresorbable scaffold implantation: From PSP to CIAO and back to facts.

  2021cites this paper
• A tough nitric oxide-eluting hydrogel coating suppresses neointimal hyperplasia on vascular stent

  2021cites this paper
• Effects of electret coating technology on coronary stent thrombogenicity

  2021cites this paper
• Effects of Simulated COVID-19 Cytokine Storm on Stent Thrombogenicity

  2021influential citation
• COBRA PzF™ coronary stent in clinical and preclinical studies: setting the stage for new antithrombotic strategies?

  2021cites this paper
• Evolución de pacientes tratados con armazones coronarios bioabsorbibles liberadores de everolimus tras su disolución completa

  2020cites this paper
• A randomized controlled trial to compare the safety and efficacy of sirolimus-eluting biodegradable polymer ultra-thin stent (SUPRAFLEX Cruz) and everolimus-eluting biodegradable polymer stent (SYNERGY) in treatment for three-vessel coronary artery disease: design of the Multivessel TALENT trial.

  2020cites this paper
• Successful Reduction of Neointimal Hyperplasia on Stainless Steel Coronary Stents by Titania Nanotexturing

  2020cites this paper
• Outcomes after complete dissolution of everolimus-eluting bioresorbable scaffolds implanted during routine practice.

  2020cites this paper
• Bioresorbable metals in cardiovascular stents: Material insights and progress

  2020cites this paper
• Two-year longitudinal evaluation of a second-generation thin-strut sirolimus-eluting bioresorbable coronary scaffold with hybrid cell design in porcine coronary arteries.

  2020cites this paper
• Five‐year follow‐up of patients who underwent everolimus‐eluting bioresorbable scaffold implantation

  2020cites this paper
• Final 5-Year Results in Randomized Japanese Patients Implanted With a Thin-Strut, Bioabsorbable, Polymer-Coated, Everolimus-Eluting SYNERGY Stent (From the EVOLVE II Study)

  2020cites this paper
• Clinical Outcomes in type 2 Diabetes with in-stent Restenosis and Late/very Late Stent Thrombosis Undergoing Primary Percutaneous Coronary Intervention: A Single-center Observational Cohort Study

  2020cites this paper
• Comparison of Durable-Polymer- and Biodegradable-Polymer-Based Newer-Generation Drug-Eluting Stents in Patients with Acute Myocardial Infarction and Prediabetes After Successful Percutaneous Coronary Intervention.

  2020cites this paper
• Everolimus-Eluting Versus Biolimus-Eluting Coronary Stent Implantation in Patients With and Without Diabetes Mellitus.

  2019cites this paper
• Acute thrombogenicity of fluoropolymer-coated versus biodegradable and polymer-free stents.

  2019cites this paper
• Impact of strut dimensions and vessel caliber on thrombosis risk of bioresorbable scaffolds using hemodynamic metrics

  2019cites this paper
• How does the failure of Absorb apply to the other bioresorbable scaffolds? An expert review of first-in-man and pivotal trials.

  2019cites this paper
• Safety and Efficacy of Polymer-Free Drug-Eluting Stents: Amphilimus-Eluting Cre8 Versus Biolimus-Eluting BioFreedom Stents

  2019cites this paper
• Cell-Specific Effects of GATA (GATA Zinc Finger Transcription Factor Family)-6 in Vascular Smooth Muscle and Endothelial Cells on Vascular Injury Neointimal Formation

  2019cites this paper
• How to SORT OUT an Additional Value From Noninferiority Stent Comparisons?

  2019influential citation
• Everolimus-Eluting Versus Biolimus-Eluting Stents With Biodegradable Polymers in Unselected Patients Undergoing Percutaneous Coronary Intervention: A Randomized Noninferiority Trial With 1-Year Follow-Up (SORT OUT VIII Trial).

  2019influential citation
• Augmented re-endothelialization and anti-inflammation of coronary drug-eluting stent by abluminal coating with magnesium hydroxide.

  2019cites this paper
• The Bioresorbable Vascular Scaffold Tale Epilogue: Overpromised, Underdelivered, Prematurely Degraded.

  2019cites this paper
• Procedural findings and early healing response after implantation of a self-apposing bioresorbable scaffold in coronary bifurcation lesions

  2019cites this paper
• Clinical Outcomes Following Implantation of Thin-Strut, Bioabsorbable Polymer-Coated, Everolimus-Eluting SYNERGY Stents.

  2019cites this paper
• Expert recommendations on the assessment of wall shear stress in human coronary arteries: existing methodologies, technical considerations, and clinical applications

  2019cites this paper
• In vitro thrombogenicity of drug-eluting and bare metal stents.

  2019cites this paper
• Five-Year Outcomes of Biodegradable Polymer Drug-Eluting Stents Versus Second-Generation Durable Polymer Drug-Eluting Stents: a Meta-Analysis of Randomized Controlled Trials

  2019cites this paper
• Expert recommendations on the assessment of wall shear stress in human coronary arteries: existing methodologies, technical considerations, and clinical applications

  2019cites this paper
• Bioresorbable Scaffold-Based Controlled Drug Delivery for Restenosis

  2018cites this paper
• Safety and efficacy of biodegradable polymer-coated thin strut sirolimus-eluting stent vs. durable polymer-coated everolimus-eluting stent in patients with acute myocardial infarction

  2018cites this paper
• Targeting PPARα for the Treatment and Understanding of Cardiovascular Diseases

  2018cites this paper
• Covering our tracks - optical coherence tomography to assess vascular healing.

  2018cites this paper
• Fully bioresorbable vascular scaffolds: lessons learned and future directions

  2018cites this paper
• Radiopaque Fully Degradable Nanocomposites for Coronary Stents

  2018cites this paper
• The effects of stenting on coronary endothelium from a molecular biological view: Time for improvement?

  2018influential citation
• Bioresorbable polymer‐coated thin strut sirolimus‐eluting stent vs durable polymer‐coated everolimus‐eluting stent in daily clinical practice: Propensity matched one‐year results from interventional cardiology network registry

  2018cites this paper
• Understanding the Impact of Stent and Scaffold Material and Strut Design on Coronary Artery Thrombosis from the Basic and Clinical Points of View

  2018cites this paper
• Histopathologic and physiologic effect of overlapping vs single coronary stents: impact of stent evolution

  2018cites this paper
• Comparison of the Absorb bioresorbable vascular scaffold to the Xience durable polymer everolimus-eluting metallic stent in routine clinical practice: a propensity score-matched analysis from a multicenter registry

  2018cites this paper
• Device specificity of vascular healing following implantation of bioresorbable vascular scaffolds and bioabsorbable polymer metallic drug-eluting stents in human coronary arteries: the ESTROFA OCT BVS vs. BP-DES study.

  2018cites this paper
• Definite stent thrombosis after drug‐eluting stent implantation in coronary bifurcation lesions: A meta‐analysis of 3,107 patients from 14 randomized trials

  2018cites this paper
• Is There Light at the End of the Thin-Strut Tunnel?

  2018cites this paper
• Bioresorbable vascular scaffolds: Time to absorb past lessons or fade away?

  2018cites this paper
• Is There Light at the End of the Thin-Strut Tunnel?: In Vitro Insights on Strut Thickness Impact on Thrombogenicity in Bioresorbable Stents or Scaffolds.

  2018cites this paper
• A new category stent with novel polyphosphazene surface modification.

  2018cites this paper
• The Synergy stent in high-bleeding risk patients: why design matters.

  2018cites this paper
• Long-term safety of bioresorbable scaffolds: insights from a network meta-analysis including 91 trials.

  2018cites this paper
• Impact of bioresorbable versus permanent polymer on longterm vessel wall inflammation and healing: a comparative drug-eluting stent experimental study.

  2018cites this paper
• Bio-resorbable polymer stents: a review of material progress and prospects

  2018cites this paper
• Novel ultrahigh molecular weight amorphous PLLA bioresorbable coronary scaffold upsized up to 0.8 mm beyond nominal diameter: An OCT and histopathology study in porcine coronary artery model

  2018cites this paper
• Possible mechanical causes of scaffold thrombosis: insights from case reports with intracoronary imaging.

  2017cites this paper
• Clinical implications of blood-material interaction and drug eluting stent polymers in review

  2017cites this paper
• Initial Experience of Bioabsorbable Polymer Everolimus-Eluting Synergy Stents in High-Risk Patients Undergoing Complex Percutaneous Coronary Intervention With Early Discontinuation of Dual-Antiplatelet Therapy.

  2017cites this paper
• The State of the Absorb Bioresorbable Scaffold: Consensus From an Expert Panel.

  2017cites this paper
• Meta-Analysis of Randomized Clinical Trials Comparing Biodegradable Polymer Drug-Eluting Stent to Second-Generation Durable Polymer Drug-Eluting Stents.

  2017cites this paper
• Second-generation magnesium scaffold Magmaris: device design and preclinical evaluation in a porcine coronary artery model.

  2017cites this paper
• Optical Coherence Tomography Findings in Patients With Coronary Stent Thrombosis

  2017cites this paper
• Zastosowanie rusztowań bioresorbowalnych w leczeniu choroby wieńcowej. Stanowisko grupy ekspertów Asocjacji Interwencji Sercowo-Naczyniowych Polskiego Towarzystwa Kardiologicznego (AISN PTK)

  2017cites this paper
• Real‐life clinical outcomes with everolimus eluting platinum chromium stent with an abluminal biodegradable polymer in patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)

  2017cites this paper
• Optical Coherence Tomography Findings in Patients With Coronary Stent Thrombosis A Report of the PRESTIGE Consortium (Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort)

  2017cites this paper
• Comparison of Acute Thrombogenicity for Metallic and Polymeric Bioabsorbable Scaffolds: Magmaris Versus Absorb in a Porcine Arteriovenous Shunt Model

  2017cites this paper
• Contemporary Drug-Eluting Stents and Vascular Response

  2017cites this paper
• Should We Still Have Bare-Metal Stents Available in Our Catheterization Laboratory?

  2017cites this paper
• Bioresorbable vascular scaffolds: implication of very late scaffold thrombosis.

  2017cites this paper
• [Bioresorbable scaffolds in the treatment of coronary artery disease. Expert consensus statement of the Association of Cardiovascular Interventions of the Polish Cardiac Society (ACVI PCS)].

  2017cites this paper